Burzynski Research Institute, Inc. Announces Presentations at the 16th
International Symposium on Pediatric Neuro-Oncology
HOUSTON, June 27, 2014
HOUSTON, June 27, 2014 /PRNewswire/ --The Burzynski Research Institute,
Inc.(BRI) announced today that it will present data on two of the Company's
clinical-stage product candidates, Antineoplaston A10 injections (Atengenal^®)
and Antineoplaston AS2-1 injections (Astugenal^®), at the 16^th International
Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to
July 2, 2014. Abstracts and presentations are now available to the public in
an online supplement in the journal, Neuro-Oncology (Neuro Oncol 2014 June;
16(Suppl 1): i1-i157). The abstract numbers are CT-004, HG-017, and MB-039.
The journal's TOC web address is
Highlights from Abstract CT-004
The abstract title is "A phase II study of Antineoplastons A10 and AS2-1 in
children with recurrent, refractory or progressive primary brain tumors based
on Protocol BT-22." Primary malignant brain tumors are the leading cause of
cancer-related death in children. This single arm two-stage phase II study
evaluated the efficacy and safety of combination of Antineoplastons A10 and
AS2-1 (ANP) in children who developed progression of primary brain tumors
during standard treatment. A total of 30 children who met the eligibility
criteria were treated according to Protocol BT-22 at the Burzynski Clinic
(BC). There were 8 cases of glioblastoma (GBM), 11 cases of diffuse intrinsic
pontine glioma (DIPG), 6 cases of anaplastic astrocytoma (AA), 2 cases of
primitive neuroectodermal tumors (sPNET) and 1 case each of atypical teratoid
rhabdoid tumor (ATR), disseminated pilocytic astrocytoma, and medulloblastoma
(PNET). Five patients (17%) obtained complete and partial responses; four
patients were diagnosed with recurrent DIPG, and one with recurrent AA. The
longest survivor is a patient diagnosed with DIPG and disseminated gliosarcoma
who remains alive more than 14 years from the treatment start. A small group
of patients reported serious toxicity including hypernatremia, somnolence, and
It is concluded that antineoplastons showed efficacy within an acceptable
profile in this group of patients with recurrent, refractory or progressive
primary brain tumors.
Titles of Abstracts HG-017 and MB-039
Abstract HG-017: A long-term survival (over 20 years) and pathologically
confirmed complete response in pediatric anaplastic astrocytoma: a case
Abstract MB-039: Long-term survival (over 20 years), complete response and
normal childhood development in medulloblastoma (PNET) without recurrence: a
The abstracts are scheduled for presentation in the poster session on June 30,
2014 from 6 PM to 8 PM.
About Burzynski Research Institute, Inc.
Burzynski Research Institute, Inc. (OTCBB:BZYR) is a biopharmaceutical company
committed to developing treatment for cancer based on genomic and epigenetic
principles. Research and development efforts are focused on basic research
and phase III clinical trials.
Forward-looking statements in this release are made pursuant to the safe
harbor provisions of the federal securities laws. Information contained in
forward-looking statements is based on current expectations and is subject to
change, and future events may differ materially from those discussed herein
due to a number of factors, including, but not limited to, risks and
uncertainties related to the ability to use Antineoplastons A10 and AS2-1.
Burzynski Research Institute, Inc. does not undertake to update any such
forward-looking statements or to publicly announce developments or events
relating to the matters described herein.
SOURCE Burzynski Research Institute, Inc.
Contact: Burzynski Research Institute, Inc.
Press spacebar to pause and continue. Press esc to stop.